or Try an Advanced Search...

    Treatment Of A Range Of Cancers Stocks List

    Symbol Grade Name % Change
    ADPT D Adaptive Biotechnologies Corporation 2.61
    ALRN D Aileron Therapeutics, Inc. -0.54
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Treatment Of A Range Of Cancer Biology Biopharmaceutical Blood Cancers Blood Test Cell Biology Diagnostic Tests Disease Drug Discovery Hematological Malignancies Infectious Diseases Inflammation Leukemia Lymphoma Metabolic Disease Molecular Biology Oncogenes P53 Peptides

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of A Range Of Cancers stocks.

    Symbol Grade Name Weight
    ARKG F ARK Genomic Revolution Multi-Sector ETF 2.27
    GERM C ETFMG Treatments Testing and Advancements ETF 0.98
    BIS D ProShares UltraShort Nasdaq Biotechnology 0.42
    EKG C First Trust Nasdaq Lux Digital Health Solutions ETF 0.19
    BTEC C Principal Healthcare Innovators Index ETF 0.11
    View all Treatment Of A Range Of Cancers ETFs...
    Compare ETFs
    Compare ARKG to BIS Compare BIS to EKG Compare GERM to EKG

        Treatment Of A Range Of Cancers Stocks Recent News

        Date Stock Title
        May 8 ADPT Adaptive Biotechnologies Corp (ADPT) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
        May 8 ADPT Adaptive Biotechnologies Corporation 2024 Q1 - Results - Earnings Call Presentation
        May 8 ADPT Adaptive Biotechnologies Corporation (ADPT) Q1 2024 Earnings Call Transcript
        May 7 ADPT Compared to Estimates, Adaptive Biotechnologies (ADPT) Q1 Earnings: A Look at Key Metrics
        May 7 ADPT Adaptive Biotechnologies Q1 2024 Earnings: Revenue Beats Estimates Amidst Challenges
        May 7 ADPT Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Misses Revenue Estimates
        May 7 ADPT Adaptive Biotechnologies GAAP EPS of -$0.33 beats by $0.02, revenue of $41.87M beats by $3.09M
        May 7 ADPT Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
        May 7 ALRN Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
        May 6 ADPT Adaptive Biotechnologies Q1 2024 Earnings Preview
        May 6 ALRN Aileron Therapeutics to Present at Two Upcoming Investor Conferences
        May 3 ALRN Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
        May 2 ALRN Aileron reports data from Cohort 1 of Phase Ib inhaled IPF treatment trial
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Treatment Of A Range Of Cancer Biology Biopharmaceutical Blood Cancers Blood Test Cell Biology Diagnostic Tests Disease Drug Discovery Hematological Malignancies Infectious Diseases Inflammation Leukemia Lymphoma Metabolic Disease Molecular Biology Oncogenes P53 Peptides
        Treatment Of A Range Of Cancers

        Browse All Tags